Leadership Team

Peter Van Vlasselaer, PhD

Founder, President and Chief Executive Officer

Herb Cross

Chief Financial Officer

Joseph Leveque, MD

Chief Medical Officer

Martin Oft, MD

Founder and Vice President of Pre-Clinical and Clinical Development

Russell Kawahata, PhD

Vice President of Technical Operations

Scott Ogg, PhD

Vice President of Corporate Development and Operations


Peter Van Vlasselaer, PhD

Founder, President and Chief Executive Officer

Peter Van Vlasselaer, PhD has over 20 years of experience in the biotech industry and is currently CEO of ARMO BioSciences. Previously, he was CEO of iPierian, ARRESTO and AVIDIA. In addition to founding ARMO, Dr. Van Vlasselaer was a co-founder of Arresto, TrueNorth and ACIR BioSciences and he was a member of the start-up teams of InterMune (ITMN) and Dendreon (DNDN). He currently serves on the boards of ARMO, Blade Therapeutics and TM3 Therapeutics. Dr. Van Vlasselaer was a post-doctoral fellow in the division of Immunology and Rheumatology at the Stanford University and at the Laboratory of Human Immunology at DNAX Research Institute, both in Palo Alto, CA. Dr. Van Vlasselaer has a bachelor degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.

Herb Cross

Chief Financial Officer

Mr. Cross has over twenty years of experience leading finance functions at both private and public companies and working with a major public accounting firm. As the Chief Financial Officer of ARMO BioSciences, Mr. Cross leads the finance, investor relations, information technology, and other administrative functions. Before joining ARMO, Mr. Cross was the Chief Financial Officer at Balance Therapeutics, Inc., where he led the finance, investor relations, and all administrative functions. Previously, Mr. Cross was Chief Financial Officer and interim Chief Executive Officer at KaloBios Pharmaceuticals, where he was responsible for overall strategic leadership and led the finance and administrative functions. Mr. Cross also served as Chief Financial Officer at Affymax. Earlier in his career, Mr. Cross was Vice President, Finance at Facet Biotech Corporation, a spin-off of PDL BioPharma, where he was Executive Director, Finance and Corporate Controller. He began his career at Arthur Andersen, LLP. Mr. Cross received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California.

Joseph Leveque, MD

Chief Medical Officer

Joseph Leveque, MD has more than 20 years of experience in the biopharmaceutical industry leading teams in the successful development and commercialization of oncology therapeutics. Dr. Leveque was the Chief Medical Officer of EMD Serono, the North America subsidiary of Merck KGaA and the Vice President and Head of U.S. Medical Oncology at Bristol-Myers Squibb (BMS) where he was involved in the development and commercialization of the first generation of immuno-oncology (IO) therapeutics, including Bavencio®, Opdivo® and Yervoy®. Prior to BMS, Dr. Leveque was the Vice President of Medical and Scientific Affairs at Onyx Pharmaceuticals, where he was involved in the development of Kyprolis® and was recognized by the Multiple Myeloma Research Foundation as one of the top 15 innovators in multiple myeloma over the last 15 years. Earlier in his career, he served as Vice President of Medical and Scientific Affairs at Cephalon Oncology and a Medical Director at Amgen, where he worked on several therapeutic programs for solid tumor and hematological malignancies. He completed his post-graduate medical training in internal medicine at the Cedars-Sinai Medical Center and earned a Medical Doctorate from University of Texas School of Medicine in Houston. He also holds a MBA from the Wharton School of the University of Pennsylvania and received a Bachelor of Arts and Sciences from the Santa Clara University.

Martin Oft, MD

Founder and Vice President of Pre-Clinical and Clinical Development

Martin Oft, MD has over 19 years of experience in Biotechnology and Pharmaceutical Research and Development. Most recently he co-founded ARMO to develop immune therapies for the treatment of cancer and other diseases. Prior to ARMO, Martin held positions at DNAX Research Inc. of Schering Plough in Palo Alto, now Merck Research Labs. There, he led multiple development teams to progress immune therapies for the treatment of cancer and led the efforts for the discovery and development of PEGylated IL-10. Previously, Martin served at Onyx Pharmaceuticals, the UCSF Cancer Center, and Boehringer Ingelheim. Martin holds an MD degree and medical license from the University of Erlangen, Germany. He performed his postdoctoral research at the Institute of Molecular Pathology in Vienna, Austria. Martin published numerous scientific articles and reviews on cancer progression and the immune response to cancer and he is an inventor on a number of cancer therapy patents.

Russell Kawahata, PhD

Vice President of Technical Operations

Russell Kawahata, PhD, has over 25 years of experience in bio-pharmaceutical development and manufacturing. Prior to joining ARMO, Russ was Vice President of Pharmaceutical Science at NeurogesX, where he directed development and manufacturing of Qutenza. Prior to that, he was Vice President of Technical Operations at InterMune where he directed development of a portfolio of clinical and commercial products including Esbriet (pirfenidone). Previously, he held positions of increasing responsibility at Xoma Corp. (XOMA), Systemix  and Connetics Corp. (CNCT) where he directed the development of Luxiq (betamethasone valerate), Olux (clobetasol proprionate), and Rogaine (minoxidil) foams. Russ received a Ph.D. in Pharmacology and Toxicology at the University of California, Davis and a B.S. in Biochemistry from the University of California, Berkeley.

Scott Ogg, PhD

Vice President of Corporate Development and Operations

Scott Ogg, PhD joined ARMO as its Vice President of Corporate Development and Operations in May 2013. Prior to joining ARMO, Scott was Director, Project and Portfolio Management at Gilead (GILD) where he managed oncology and hepatitis programs. Scott was on the start-up team of ARRESTO BioSciences where he played an instrumental role in the acquisition of the company by Gilead and the completion of the Series B and C financings as Senior Director of Project and Alliance Management. Previously, he held positions of increasing responsibility at Exelixis (EXEL) and Nektar Therapeutics (NKTR) where he managed the early development of MOVANTIK (naloxegol). Scott completed post-doctoral studies at Harvard University Medical School/Massachusetts General Hospital and received a Ph.D. in Cellular & Molecular Physiology from Tufts University Sackler School of Graduate Biomedical Sciences and a B.A. in Biology from Albion College. He is author and inventor on several publications and patents.